# Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12

> **NCT06854601** · PHASE3 · COMPLETED · sponsor: **Pharmasoft** · enrollment: 333 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)
- Anxiety Disorders and Symptoms

## Interventions

- **DRUG:** Mexidol
- **DRUG:** Placebo
- **DRUG:** Mexidol + Placebo

## Key facts

- **NCT ID:** NCT06854601
- **Lead sponsor:** Pharmasoft
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-13
- **Primary completion:** 2020-07-13
- **Final completion:** 2020-07-13
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06854601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06854601, "Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06854601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*